scholarly journals Comparison of molecular testing methods for detecting Taylorella equigenitalis

2021 ◽  
Vol 53 (S56) ◽  
pp. 31-31
Keyword(s):  
Molecular Testing ◽  
Testing Methods ◽  
Taylorella Equigenitalis

scholarly journals BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Ryan J. Sullivan ◽  
Keith T. Flaherty
Keyword(s):  
Standard Of Care ◽  
Diagnostic Techniques ◽  
Therapeutic Interventions ◽  
Molecular Testing ◽  
Braf Inhibitors ◽  
Testing Methods ◽  
Braf Mutations ◽  
Initial Discovery ◽  
Braf Mutant ◽  
Mutant Braf

Since the initial discovery that a subset of patients with cutaneous melanoma harbor BRAF mutations, substantial research has been focused on determining the pathologic consequences of BRAF mutations, optimizing diagnostic techniques to identify these mutations, and developing therapeutic interventions to inhibit the function of this target in mutation-bearing tumors. Recently, advances have been made which are revolutionizing the standard of care for patients with BRAF mutant melanoma. This paper provides an overview on the pathogenic ramifications of mutant BRAF signaling, the latest molecular testing methods to detect BRAF mutations, and the most recent clinical data of BRAF pathway inhibitors in patients with melanoma and BRAF mutations. Finally, emerging mechanisms of resistance to BRAF inhibitors and ways of overcoming this resistance are discussed.

scholarly journals Sensitive molecular testing methods can demonstrate NSCLC driver mutations in malignant pleural effusion despite non-malignant cytology

2019 ◽  
Vol 8 (4) ◽  
pp. 513-518 ◽  
Author(s):  
Daniel P. Steinfort ◽  
Sevastjan Kranz ◽  
Anthony Dowers ◽  
Leakhena Leas ◽  
Voula Dimitriadis ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Driver Mutations ◽  
Molecular Testing ◽  
Testing Methods

scholarly journals Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy

2016 ◽  
Vol 22 (4) ◽  
pp. 380.e1-380.e7 ◽  
Author(s):  
L. Richardson ◽  
J. Brite ◽  
M. Del Castillo ◽  
T. Childers ◽  
A. Sheahan ◽  
...  
Keyword(s):  
Respiratory Virus ◽  
Haematological Malignancy ◽  
Molecular Testing ◽  
Testing Methods ◽  
Virus Shedding

scholarly journals A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors

2020 ◽  
Vol 12 ◽  
pp. 175883592097561
Author(s):  
Anna Forsythe ◽  
Wei Zhang ◽  
Uwe Phillip Strauss ◽  
Marc Fellous ◽  
Maesumeh Korei ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Gene Fusion ◽  
Meta Analysis ◽  
Bone Sarcoma ◽  
Point Estimate ◽  
Molecular Testing ◽  
Receptor Kinase ◽  
Testing Methods ◽  
Kinase Gene ◽  
Tyrosine Receptor Kinase

Introduction: The research objective was to systematically review evidence on neurotrophic tyrosine receptor kinase ( NTRK) gene fusion frequency in solid tumors. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic literature review (SLR) was conducted of studies published from January 1987 to 2 January 2020. Selected studies were appraised for use in meta-analysis, with frequency reported as a point estimate with confidence intervals, to estimate NTRK gene fusion tumor incidence and prevalence. Results: The SLR identified 222 studies from North America ( n = 122), Europe ( n = 33), Asia ( n = 41), Brazil ( n = 5), Australia ( n = 2), and multi-continental ( n = 19) reporting NTRK gene fusion frequencies across 101 histologies. Studies were prospective ( n = 43) and retrospective ( n = 179). Testing methods involved DNA ( n = 93), RNA ( n = 72), combined DNA/RNA ( n = 48), protein [immunohistochemistry (IHC), n = 5], and unreported ( n = 5). Sample sizes ranged from 1 to 66,871. Of the 222 studies, 107 were suitable for meta-analysis. Highest NTRK gene fusion frequencies were reported in rare cancers: infantile/congenital fibrosarcoma (90.56%, 95% CI 67.42–100.00), secretory breast cancer (92.87%, 95% CI 72.62–100.00), and congenital mesoblastic nephroma (21.52%, 95% CI 13.06–32.20). Lower frequencies were reported in non-small cell lung cancer (0.17%, 95% CI 0.09–0.25), colorectal adenocarcinoma (0.26%, 95% CI 0.15–0.36), cutaneous melanoma (0.31%, 95% CI 0.07–0.55), and non-secretory breast carcinoma (0.60%, 95% CI 0.00–1.50). Reported frequency was ~0% for some cancers: mesothelioma, renal cell carcinoma, prostate cancer, and bone sarcoma. Estimated global overall NTRK gene fusion tumour incidence and 5-year prevalence in 2018 was 0.52 and 1.52 per 100,000 persons, respectively. Conclusion: This research confirms the rarity and varying frequency of NTRK gene fusion across tumor types. Limitations included relatively low historic NTRK gene fusion testing and reporting, limited study samples for some cancers, and suboptimal molecular testing methods. In this rapidly developing area, gold-standard testing methods and companion diagnostics are needed to capture all NTRK gene fusions.

Catching the Flu: Clinical Implications of Two Different Molecular Testing Methods Used During the 2013-2014 Influenza Season

CHEST Journal ◽  
2015 ◽  
Vol 148 (4) ◽  
pp. 117A
Author(s):  
Nicholas Csikesz ◽  
Sonja Chen ◽  
Jacob Smith ◽  
Roberta Dickenson ◽  
Kimberle Chapin ◽  
...  
Keyword(s):  
Influenza Season ◽  
Clinical Implications ◽  
Molecular Testing ◽  
Testing Methods

scholarly journals Comparison of rapid molecular testing methods for detecting respiratory viruses in emergency care: a prospective study

2021 ◽  
pp. 1-8
Author(s):  
Dagfinn Lunde Markussen ◽  
Harleen M. S. Grewal ◽  
Siri Tandberg Knoop ◽  
Sondre Serigstad ◽  
Øyvind Kommedal ◽  
...  
Keyword(s):  
Prospective Study ◽  
Emergency Care ◽  
Respiratory Viruses ◽  
Molecular Testing ◽  
Testing Methods ◽  
A Prospective Study

Complications and Economic Burden Associated with Obtaining Tissue for Diagnosis and Molecular Analysis in Patients with Non-Small Cell Lung Cancer (NSCLC) in the US (Preprint)

2018 ◽  
Author(s):  
Ronan Kelly ◽  
Ralph Turner ◽  
Yen-Wen Chen ◽  
James R. Rigas ◽  
Ancilla W. Fernandes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Molecular Testing ◽  
Administrative Claims ◽  
Complication Rates ◽  
Testing Methods ◽  
Small Cell Lung ◽  
The Us

BACKGROUND Tissue biopsy to identify targetable genomic and immunologic alterations is the mainstay of managing patients with non-small cell lung cancer (NSCLC); however, little is known about the associated economic impact and complication rates. OBJECTIVE This study assesses the frequency, complications and costs of diagnostic and post-progression biopsy. METHODS This retrospective, observational study was conducted using administrative claims data from over 30 million commercially insured individuals in the US (2006-2014). Data were analyzed for the overall population and by time of biopsy (diagnostic or post-progression). RESULTS Of 20,013 eligible patients, 13,411 (67%) received a diagnostic biopsy, whereas only 2,056 (10%) received a post-progression biopsy; mean cost: $9,977 and $16,806, respectively. Complication rates were similar at diagnosis and post-progression, on the day of biopsy (10% vs 7%) and within 30 days (63% vs 61%). Mean costs were higher among patients with a complication vs those without, on the day of biopsy (diagnostic: $12,030 vs $6,508; post-progression: $22,593 vs $7,812) and within 30 days (diagnostic: $24,968 vs $15,988; post-progression: $30,293 vs $12,494) (P< .001 for all comparisons). CONCLUSIONS From 2006 to 2014, post-progression biopsies were not common practice in NSCLC. Complication rates were similar at diagnosis and post-progression, with mean costs higher among patients with a complication than those without. With increasing demands for effective novel targeted therapies and safe testing methods for patients, providers, and payers, these data may be valuable in determining the budget impact and comparing complication rates with newer, less invasive molecular testing methods, including plasma circulating tumor DNA testing.

Sign in / Sign up

Export Citation Format

Share Document